Enabling Consistency in Pluripotent Stem Cell-Derived Products for Research and Development and Clinical Applications Through Material Standards

Author:

French Anna1,Bravery Christopher2,Smith James1,Chandra Amit3,Archibald Peter3,Gold Joseph D.4,Artzi Natalie56,Kim Hae-Won7,Barker Richard W.1,Meissner Alexander8910,Wu Joseph C.41112,Knowles Jonathan C.1314,Williams David3,García-Cardeña Guillermo91516,Sipp Doug17,Oh Steve18,Loring Jeanne F.1920,Rao Mahendra S.21,Reeve Brock8,Wall Ivan1132223,Carr Andrew J.124,Bure Kim25,Stacey Glyn26,Karp Jeffrey M.82728,Snyder Evan Y.293031,Brindley David A.18103233

Affiliation:

1. Oxford–UCL Centre for the Advancement of Sustainable Medical Innovation, University of Oxford, Oxford, United Kingdom

2. Consulting on Advanced Biologicals Ltd., London, United Kingdom

3. Centre for Biological Engineering, Wolfson School of Mechanical and Manufacturing Engineering, Loughborough University, Loughborough, United Kingdom

4. Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, California, USA

5. Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA

6. Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA

7. Department of Dental Biomaterials, School of Dentistry, Dankook University, Cheonan, Republic of Korea

8. Harvard Stem Cell Institute, Cambridge, Massachusetts

9. Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA

10. Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts, USA

11. Department of Medicine, Stanford University School of Medicine, Stanford, California, USA

12. Department of Radiology, Stanford University School of Medicine, Stanford, California, USA

13. Department of Nanobiomedical Science BK21 Plus NBM Global Research Center of Regenerative Medicine, Dankook University, Cheonan, Republic of Korea

14. Division of Biomaterials and Tissue Engineering, UCL Eastman Dental Institute, University College London, London, United Kingdom

15. Center for Excellence in Vascular Biology, Department of Pathology, Division of Biomedical Engineering, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA

16. Program in Developmental and Regenerative Biology, Harvard Medical School, Boston, Massachusetts, USA

17. RIKEN Center for Developmental Biology, Kobe, Japan

18. Bioprocessing Technology Institute, A*STAR Agency for Science, Technology and Research, Singapore

19. Department of Chemical Physiology, Scripps Research Institute, La Jolla, California, USA

20. Center for Regenerative Medicine, Scripps Research Institute, La Jolla, California, USA

21. NIH Center for Regenerative Medicine, Bethesda, Maryland, USA

22. Department of Biochemical Engineering, UCL School of Pharmacy, University College London, London, United Kingdom

23. Biomaterials and Tissue Engineering Laboratory, Department of Nanobiomedical Science and WCU Research Center, Dankook University, Cheonan, Republic of Korea

24. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Nuffield Orthopaedic Centre, University of Oxford, Oxford, United Kingdom

25. TAP Biosystems, Royston, United Kingdom

26. National Institute for Biological Standards and Control, a Centre of the MHRA, South Mimms, United Kingdom

27. Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA

28. Center for Regenerative Therapeutics and Department of Medicine, Division of Biomedical Engineering, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA

29. Sanford-Burnham Medical Research Institute, La Jolla, California, USA

30. Department of Pediatrics, School of Medicine, University of California, San Diego, La Jolla, California, USA

31. Sanford Consortium for Regenerative Medicine, La Jolla, California, USA

32. Saïd Business School, University of Oxford, Oxford, United Kingdom

33. Centre for Behavioural Medicine, UCL School of Pharmacy, University College London, London, United Kingdom

Abstract

Abstract Summary There is a need for physical standards (reference materials) to ensure both reproducibility and consistency in the production of somatic cell types from human pluripotent stem cell (hPSC) sources. We have outlined the need for reference materials (RMs) in relation to the unique properties and concerns surrounding hPSC-derived products and suggest in-house approaches to RM generation relevant to basic research, drug screening, and therapeutic applications. hPSCs have an unparalleled potential as a source of somatic cells for drug screening, disease modeling, and therapeutic application. Undefined variation and product variability after differentiation to the lineage or cell type of interest impede efficient translation and can obscure the evaluation of clinical safety and efficacy. Moreover, in the absence of a consistent population, data generated from in vitro studies could be unreliable and irreproducible. Efforts to devise approaches and tools that facilitate improved consistency of hPSC-derived products, both as development tools and therapeutic products, will aid translation. Standards exist in both written and physical form; however, because many unknown factors persist in the field, premature written standards could inhibit rather than promote innovation and translation. We focused on the derivation of physical standard RMs. We outline the need for RMs and assess the approaches to in-house RM generation for hPSC-derived products, a critical tool for the analysis and control of product variation that can be applied by researchers and developers. We then explore potential routes for the generation of RMs, including both cellular and noncellular materials and novel methods that might provide valuable tools to measure and account for variation. Multiparametric techniques to identify “signatures” for therapeutically relevant cell types, such as neurons and cardiomyocytes that can be derived from hPSCs, would be of significant utility, although physical RMs will be required for clinical purposes.

Publisher

Oxford University Press (OUP)

Subject

Cell Biology,Developmental Biology,General Medicine

Reference34 articles.

1. The role of standards in innovation;Allen;Technol Forecast Soc Change,2000

2. Standards can help bring cell therapy products to market;Sheridan;Bioprocess Int,2012

3. Drug development: Raise standards for preclinical cancer research;Begley;Nature,2012

4. Induced pluripotent stem cells—Opportunities for disease modelling and drug discovery;Grskovic;Nat Rev Drug Discov,2011

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3